GRNVAC1

Asterias Biotherapeutics, Inc. · Phase 2 active Biologic

At a glance

Generic name	GRNVAC1
Sponsor	Asterias Biotherapeutics, Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRNVAC1 CI brief — competitive landscape report
GRNVAC1 updates RSS · CI watch RSS
Asterias Biotherapeutics, Inc. portfolio CI